The rise of Viagra and its influence on the pharmaceutical landscape presents a complex question for investors. While the first sales statistics were impressive, the intellectual property has expired, leading to a flood of off-brand alternatives that are chipping away at earnings. Furthermore, the industry is facing challenges related to demogra… Read More